Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO European Region, January - December 2020: a systematic review

A Vaughan, EF Duffell, GS Friedl, DS Lemos, T Funk, A Nardone, M Valenciano, L Subissi, I Bergeri, E Broberg, P Penttinen, R Pebody, M Keramarou
doi: https://doi.org/10.1101/2021.12.02.21266897

Article Information

doi 
https://doi.org/10.1101/2021.12.02.21266897
History 
  • December 5, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. A Vaughan1,
  2. EF Duffell2,
  3. GS Friedl1,
  4. DS Lemos1,
  5. T Funk2,
  6. A Nardone3,
  7. M Valenciano3,
  8. L Subissi4,
  9. I Bergeri4,
  10. E Broberg2,
  11. P Penttinen2,
  12. R Pebody1 and
  13. M Keramarou2
  1. 1World Health Organization Regional Office for Europe, Copenhagen, Denmark
  2. 2European Centre for Disease Prevention and Control, Stockholm, Sweden
  3. 3Epiconcept, Paris, France
  4. 4World Health Organization, Geneva, Switzerland
  1. * Corresponding author; email: vaughana{at}who.int
Back to top
Posted December 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO European Region, January - December 2020: a systematic review
A Vaughan, EF Duffell, GS Friedl, DS Lemos, T Funk, A Nardone, M Valenciano, L Subissi, I Bergeri, E Broberg, P Penttinen, R Pebody, M Keramarou
medRxiv 2021.12.02.21266897; doi: https://doi.org/10.1101/2021.12.02.21266897
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area